Company: MIRA
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010301
Chunk: 14

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-05-14
Form: 10-Q
Item: Item 8
Chunk 14
---
 patients in our clinical trials;

 13 

    ●
    the
    timing or likelihood of the accomplishment of various scientific, clinical, regulatory, and other product development objectives;

    ●
    the
    pricing and reimbursement of our product candidates, if approved;

    ●
    the
    rate and degree of market acceptance of our product candidates, if approved;

    ●
    the
    implementation of our business model and strategic plans for our business, product candidates, and technology;

    ●
    the
    scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;

    ●
    developments
    relating to our competitors and our industry;

    ●
    the
    development of major public health concerns and the future impact of such concerns on our clinical trials, business operations and
    funding requirements; and

    ●
    other
    risks and factors listed under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024
    and elsewhere in this Report.

Given
the risks and uncertainties set forth in this Report, you are cautioned not to place undue reliance on such forward-looking statements.
The forward-looking statements contained in this Report are not guarantees of future performance and our actual results of operations,
financial condition, and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking
statements contained in this Report. In addition, even if our results of operations, financial condition and liquidity, and events in
the industry in which we operate, are consistent with the forward-looking statements contained in this Report, they may not be predictive
of results or developments in future periods. In evaluating our business, you should carefully consider the information set forth under
the heading “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the
SEC on March 28, 2025.

Any
forward-looking statement that we make in this Report speaks only as of the date of such statement. Except as required by federal securities
laws, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking
statements, whether as a result of new information, future events or otherwise, after the date of this Report.

 14 

Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The
following